Cell Biology Program

The Kristian Helin Lab

Research

Kristian Helin
Kristian Helin, PhD
Adjunct, Cell Biology Program, SKI

The Helin lab studies how fundamental biological processes are regulated and how these become perturbed in human disease, particularly in cancer. Our vision is that our research can play a role in developing new therapies for people with cancer and at the same time provide new insights into mechanisms regulating transcription, stem cell identity, and differentiation. Our research is focused on how chromatin-associated proteins regulate transcription and control cell-fate decisions. To do this we use a host of different methods in biochemistry, cell biology, and genetics (including mouse genetics) and a number of high-throughput genetic methods to identify potential novel therapeutic targets. 

Research Projects

Publications

Radzisheuskaya A, Shliaha PV, Grinev V, Lorenzini E, Kovalchuk S, Shlyueva D, Gorshkov V, Hendrickson RC, Jensen ON, Helin K. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat Struct Mol Biol. 2019 Nov;26(11):999-1012. doi: 10.1038/s41594-019-0313-z. Epub 2019 Oct 14.

Højfeldt JW, Hedehus L, Laugesen A, Tatar T, Wiehle L, Helin K. Non-core Subunits of the PRC2 Complex Are Collectively Required for Its Target-Site Specificity. Mol Cell. 2019 Nov 7;76(3):423-436.e3. doi: 10.1016/j.molcel.2019.07.031. Epub 2019 Sep 11.
 

Rasmussen KD, Berest I, Keβler S, Nishimura K, Simón-Carrasco L, Vassiliou GS, Pedersen MT, Christensen J, Zaugg JB, Helin KTET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells. Genome Res. 2019 Apr;29(4):564-575. doi: 10.1101/gr.239277.118. Epub 2019 Feb 22.

Højfeldt J, Laugesen A, Willumsen BM, Damhofer H, Hedehus L, Tvardovskiy A, Mohammad F, Jensen ON & Helin K. Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2. Nature Structural & Molecular Biology. (2018)

Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt, JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM & Helin K. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nature Medicine 4, 483-492, doi: 10.1038/nm.4293 (2017).

View All Publications

People

Kristian Helin

Kristian Helin, PhD

Adjunct, Cell Biology Program, SKI

  • Cancer biologist Kristian Helin studies how genetic and epigenetic mechanisms affect transcription and cell-fate decisions, and how their deregulation contributes to cancer.
  • PhD, University of Coepenhagen
[email protected]
Email Address
646-888-3545
Office Phone

Members

Iris Muller
Iris Muller

Postdoctoral Fellow

Aliaksandra Radsizheuskaya
Aliaksandra Radsizheuskaya

Postdoctoral Fellow

Lab Affiliations

Achievements

  • Kirsten og Freddy Johansens pre-clinical Research Prize (2018)
  • Director Ib Henriksen’s Foundation’s research prize (2015)
  • The Anders Jahre Senior Medical Prize (2014)
  • The Carlsberg Foundation’s Research Prize in Natural Sciences (2012)
  • The innovation prize of University of Copenhagen (2011)
Read more
  • The Novo Nordisk Prize (2008)
  • Elected to The Royal Danish Academy of Sciences and Letters (2008)
  • Elected member of European Molecular Biology Organisation (2002)

Lab News & Events

Upcoming event

Proteolytic Regulation of Pyroptosis

This seminar will be conducted by Zoom Webinar.

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Kristian Helin discloses the following relationships and financial interests:

  • Cell Press
    Provision of Services (uncompensated)
  • European Institute of Oncology
    Provision of Services
  • European Molecular Biology Organization
    Provision of Services (uncompensated)
  • Hannibal Health Innovation ApS
    Provision of Services (uncompensated)
  • Inthera Bioscience AG
    Provision of Services
  • Novo Holdings A/S
    Provision of Services
  • University of Copenhagen
    Provision of Services (uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures